William Visit 3 - New patient with long-standing type 2 diabetes, 3-month follow-up
| Title: | William Visit 3 - New patient with long-standing type 2 diabetes, 3-month follow-up |
| Topic: | Diabetology |
| Relevant Terms: | Diabetes, Diabetes Complications, Endocrinology, Macrovascular Disease, Microvascular Disease |
| Primary Audience: | Primary care providers (MDs/ DOs/ NPs/ PAs) and other healthcare professionals who treat adults with diabetes |
| Launch Date: | 03-Aug-09 |
| Credits: | 0.5 AMA PRA Category 1 Credit™ |
| Expiration Date: | 31-Dec-12 |
Learning Objectives
After completion of this activity, participants should be better able to:
- Explain the natural history of type 2 diabetes including the evolution of insulin resistance and insulin secretory decline as key factors in the clinical progression of the disease
- Recognize the role of the incretin system in normal physiology and in the pathophysiology and treatment of type 2 diabetes
- Describe the process of selecting and advancing treatment regimens for type 2 diabetes in the outpatient setting that balance physiologic needs with individualized self-care considerations
- List common obstacles to treatment advancement, including patient-based issues such as weight management issues, culture and self-care abilities, and clinician-based issues (such as office system inadequacy) that can contribute to therapeutic inertia
- Choose appropriate tests and data collection to assist in the diagnosis of a patient with diabetes who is not at goal
- Interpret test results, including lab values and glucose patterns, and analyze consulting reports from other clinicians, such as dietitians, diabetes educators, cardiologists, and ophthalmologists
- Develop and implement office-based systems to manage treatment and facilitate therapeutic advancement
Faculty
Kenneth Snow, MD, MBA
Assistant Professor of Clinical Medicine
Harvard Medical School
Acting Chief, Adult Diabetes
Joslin Diabetes Center
Boston, MA
Jerry P. Palmer, MD
Professor of Medicine
University of Washington
Director, Department of Endocrinology
VA Puget Sound Health Care System
Seattle, WA
Arturo R. Rolla, MD
Assistant Clinical Professor of Medicine
Harvard Medical School
Assistant Clinical Professor of Medicine
Tufts University School of Medicine
Endocrinologist, Beth Israel Deaconess Medical Center
Boston, MA
Alissa Segal, PharmD, CDE
Associate Professor of Pharmacy Practice
Massachusetts College of Pharmacy & Health Sciences
Clinical Pharmacist
Joslin Diabetes Center
Boston, MA
Medical Director/Senior Editor:
Enrique Caballero, MD
Assistant Professor of Medicine
Harvard Medical School
Director, Medical Affairs, Professional Education
Director, Latino Diabetes Initiative
Joslin Diabetes Center
Boston, MA
Assistant Professor of Clinical Medicine
Harvard Medical School
Acting Chief, Adult Diabetes
Joslin Diabetes Center
Boston, MA
Jerry P. Palmer, MD Professor of Medicine
University of Washington
Director, Department of Endocrinology
VA Puget Sound Health Care System
Seattle, WA
Arturo R. Rolla, MD Assistant Clinical Professor of Medicine
Harvard Medical School
Assistant Clinical Professor of Medicine
Tufts University School of Medicine
Endocrinologist, Beth Israel Deaconess Medical Center
Boston, MA
Alissa Segal, PharmD, CDEAssociate Professor of Pharmacy Practice
Massachusetts College of Pharmacy & Health Sciences
Clinical Pharmacist
Joslin Diabetes Center
Boston, MA
Medical Director/Senior Editor: Enrique Caballero, MD
Assistant Professor of Medicine
Harvard Medical School
Director, Medical Affairs, Professional Education
Director, Latino Diabetes Initiative
Joslin Diabetes Center
Boston, MA
Planning Committee:
Julie Brown
Director
Professional Education
Joslin Diabetes Center
Boston, MA
James Neighbours, MEd
Assistant Director, Education Technology Services
Professional Education
Joslin Diabetes Center
Boston, MA
DISCLOSURE POLICY STATEMENT
As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center, Boston, must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services with the exception of nonprofit or government organizations and non–healthcare-related companies, which are exempt.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.
If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of the Joslin Diabetes Center.
Dr. Snow has no relevant financial relationships.
Dr. Palmer receives grant/research support from Amylin Pharmaceuticals, Inc. and GlaxoSmithKline, and is a consultant for Amgen USA Inc., Diamyd Medical AB, Eli Lilly and Company, GlaxoSmithKline, Merck & Co. Inc., and Pfizer Inc.
Dr. Rolla is on the speakers bureau for Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk Inc., and F. Hoffman-La Roche Ltd.
Ms. Segal receives grant/research support from Walgreens Co.
Dr. Caballero is a consultant for Amylin Pharmaceuticals, Inc. Eli Lilly and Company, Pfizer Inc, sanofi-aventis U.S. LLC and Takeda Pharmaceuticals North America, Inc.
Dr. Beaser is on the academic advisory board for AstraZeneca Pharmaceuticals LP and Bristol-Myers Squibb Company.
Ms. Brown has no relevant financial relationships.
Mr. Neighbours has no relevant financial relationships.
ACCREDITATION STATEMENT
The Joslin Diabetes Center, Boston, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION
Joslin Diabetes Center designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
To Obtain CME Credits
• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the posttest and activity evaluation.
• Physicians who successfully complete the post-test and evaluation will receive CME credit.
• You must score with a 60% or higher on the post-test to receive credit for this activity.
• All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
Release Date: August 3, 2009
Expiration Date: December 31, 2012
ACKNOWLEDGEMENT
This activity is sponsored by Joslin Diabetes Center.
This activity is supported by an educational grant from Takeda Pharmaceuticals North America, Inc.
If you have any questions regarding this activity, send an email to profedweb@joslin.harvard.edu.
Copyright © 2011 by Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Joslin Diabetes Center is prohibited.
Richard S. Beaser, MD
Associate Clinical Professor of Medicine
Harvard Medical School
Medical Executive Director
Professional Education
Joslin Diabetes Center
Boston, MA
Julie Brown
Director
Professional Education
Joslin Diabetes Center
Boston, MA
James Neighbours, MEd
Assistant Director, Education Technology Services
Professional Education
Joslin Diabetes Center
Boston, MA
DISCLOSURE POLICY STATEMENT
As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center, Boston, must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services with the exception of nonprofit or government organizations and non–healthcare-related companies, which are exempt.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.
If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of the Joslin Diabetes Center.
Dr. Snow has no relevant financial relationships.
Dr. Palmer receives grant/research support from Amylin Pharmaceuticals, Inc. and GlaxoSmithKline, and is a consultant for Amgen USA Inc., Diamyd Medical AB, Eli Lilly and Company, GlaxoSmithKline, Merck & Co. Inc., and Pfizer Inc.
Dr. Rolla is on the speakers bureau for Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk Inc., and F. Hoffman-La Roche Ltd.
Ms. Segal receives grant/research support from Walgreens Co.
Dr. Caballero is a consultant for Amylin Pharmaceuticals, Inc. Eli Lilly and Company, Pfizer Inc, sanofi-aventis U.S. LLC and Takeda Pharmaceuticals North America, Inc.
Dr. Beaser is on the academic advisory board for AstraZeneca Pharmaceuticals LP and Bristol-Myers Squibb Company.
Ms. Brown has no relevant financial relationships.
Mr. Neighbours has no relevant financial relationships.
ACCREDITATION STATEMENT
The Joslin Diabetes Center, Boston, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION
Joslin Diabetes Center designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
To Obtain CME Credits
• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the posttest and activity evaluation.
• Physicians who successfully complete the post-test and evaluation will receive CME credit.
• You must score with a 60% or higher on the post-test to receive credit for this activity.
• All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
| PC Internet Explorer (v6 or greater), or Firefox |
MAC Safari |
Release Date: August 3, 2009
Expiration Date: December 31, 2012
ACKNOWLEDGEMENT
This activity is sponsored by Joslin Diabetes Center.
This activity is supported by an educational grant from Takeda Pharmaceuticals North America, Inc.
If you have any questions regarding this activity, send an email to profedweb@joslin.harvard.edu.
Copyright © 2011 by Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Joslin Diabetes Center is prohibited.
